In the reported quarter, net realized prices declined 4% ... model estimate of $2.0 billion. Zepbound sales were also in line with Lilly’s preliminary estimate. Though Mounjaro and Zepbound's ...

Great Britain will be the first major market to be supplied with the drug in the multi-shot pen injector ... the Mounjaro KwikPen can be used to treat adults with type 2 diabetes and for weight ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Sales of GLP1 therapy tirzepatide marketed as Mounjaro ... 4 billion reflecting 128% year-over-year growth. Nonincretin revenue climbed 20% year-over-year fueled by diabetes drug Jardiance ($1.2 ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

compared to $2.49 from a year ago, beating the consensus of $4.94. Mounjaro sales jumped 60% to $3.53 billion. Sales of Verzenio (a breast cancer drug) increased 36% to $1.56 billion, and sales of ...

From the 17th of February this year, Mounjaro will be licenced for use as a treatment in Ireland for both type 2 diabetes and obesity. Maura Fay spoke to Dr Michael Crotty, clinical lead for ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue increase Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound ...